Cargando…

Clinical trial design in the era of precision medicine

Recent rapid biotechnological breakthroughs have led to the identification of complex and unique molecular features that drive malignancies. Precision medicine has exploited next-generation sequencing and matched targeted therapy/immunotherapy deployment to successfully transform the outlook for sev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fountzilas, Elena, Tsimberidou, Apostolia M., Vo, Henry Hiep, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428375/ https://www.ncbi.nlm.nih.gov/pubmed/36045401 http://dx.doi.org/10.1186/s13073-022-01102-1

Ejemplares similares

Dataset of phase I and II immunotherapy clinical trials used for a meta-analysis to assess the role of biomarkers in treatment outcomes in diverse cancers
por: Fountzilas, Elena, et al.
Publicado: (2023)

Precision Oncology: Evolving Clinical Trials across Tumor Types
por: Song, I-Wen, et al.
Publicado: (2023)

Circulating tumor DNA analysis in the era of precision oncology
por: Said, Rabih, et al.
Publicado: (2020)

New clinical trial designs in the era of precision medicine
por: Garralda, Elena, et al.
Publicado: (2019)

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors
por: Subbiah, Ishwaria M., et al.
Publicado: (2018)

Dermatologic Disease-Directed Targeted Therapy (D(3)T(2)): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology
por: Cohen, Philip R., et al.
Publicado: (2022)

Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits
por: Fountzilas, Elena, et al.
Publicado: (2018)

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
por: Janku, Filip, et al.
Publicado: (2014)

Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series
por: Naqvi, Mohammad Faraz, et al.
Publicado: (2021)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2019)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine
por: Moore, Donald C., et al.
Publicado: (2023)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2021)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase
por: Geifman, Nophar, et al.
Publicado: (2014)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2015)

Molecular landscape of pancreatic cancer: implications for current clinical trials
por: Heestand, Gregory M., et al.
Publicado: (2015)

First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
por: Tsimberidou, Apostolia Maria, et al.
Publicado: (2023)

Ethical considerations of neuro-oncology trial design in the era of precision medicine
por: Gupta, Saksham, et al.
Publicado: (2017)

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
por: Liu, Sariah, et al.
Publicado: (2016)

The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments
por: Boichard, Amélie, et al.
Publicado: (2020)

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
por: Falchook, Gerald S., et al.
Publicado: (2013)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience
por: Corrales-Medina, Fernando F., et al.
Publicado: (2014)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Neuroblastoma in the Era of Precision Medicine: A Clinical Review
por: Wahba, Andrew, et al.
Publicado: (2023)

Precision Medicine and Precision Nursing: The Era of Biomarkers and Precision Health
por: Ielapi, Nicola, et al.
Publicado: (2020)

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
por: Hou, Ming-Mo, et al.
Publicado: (2014)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance
por: Wheler, Jennifer, et al.
Publicado: (2015)

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
por: Wheler, Jennifer, et al.
Publicado: (2013)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Fool’s gold, lost treasures, and the randomized clinical trial
por: Stewart, David J, et al.
Publicado: (2013)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Antibiotic stewardship in the era of precision medicine
por: Watkins, Richard R
Publicado: (2022)

Gastric Cancer in the Era of Precision Medicine
por: Liu, Xi, et al.
Publicado: (2017)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_id8r502d76us58iigmp326kah0